John Theurer Cancer Center Announces Positive Results With New Targeted Biological In Indolent Non-Hodgkin Lymphoma

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

HACKENSACK, N.J.--(BUSINESS WIRE)--Andre Goy, M.D., Chairman and Director of John Theurer Cancer Center, Chief of the Lymphoma Program and Chief Science Officer and Director of Research and Innovation for Regional Cancer Care Associates, announced today positive results from a phase II study of patients with indolent non-Hodgkin lymphoma (iNHL) published in the New England Journal of Medicine (NEJM). The trial was conducted by Dr. Goy and a number of researchers and physicians from leading institutions around the world.

Help employers find you! Check out all the jobs and post your resume.
MORE ON THIS TOPIC